AdAlta (ASX:1AD) is bringing cellular immunotherapy products from Asian to western markets to drive value creation.

AdAlta (ASX:1AD) has unveiled a new grand plan to take cell therapy candidates from Southeast Asia, firm them up in Australian early-stage tests, and then licence those products if successful to ...

AdAlta Ltd. ( ($AU:1AD) ) just unveiled an announcement. AdAlta Limited is set to host an investor webinar to discuss its ‘East to West’ cellular ...

Discover outperforming stocks and invest smarter with Top Smart Score Stocks Filter, analyze, and streamline your search for investment opportunities using Tipranks' Stock Screener AdAlta Ltd ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...

The recent price decline of 12% in AdAlta Limited's (ASX:1AD) stock may have disappointed insiders who bought AU$99.5k worth of shares at an average price of AU$0.026 in the past 12 months. Insiders ...